Remove

o a collection of information unless it contains a valid OMB control number.

U.S.PATENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10816435				
Filing Date		2004-03-31				
First Named Inventor	G.Y.	TSAO et al.				
Art Unit		2111				
Examiner Name Gopa		d C. Ray				
Attorney Docket Number		P19002				

Examiner   Cite   Patent Number		Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where les or Relevant
	1	6760783		2004-07-06	Велту			
	2	7010633		2006-03-07	Arndt et al.			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Cite Initial* No Publication Numb		Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document Pages, Columns, Lin Relevant Passages Figures Appear			
	1	20010037397		2001-11-01	Boucher et al.			
	2	20020152327		2002-10-17	Kagan et al.			
E 17	3	20030065856		2003-04-03	Kagan et al.			
	4	20040017819		2004-01-29	Kagan et al.			

#### 

	5	20040027374		2004-0	2-12	Cime et al.				
	6	20040103225		2004-0	5-27	McAlpine et al	McAlpine et al.			
	7	20050228922		2005-10-13		Tsao et al.				
	8	20060004983		2006-01-05		Tsao et al.				
	9	20060133396		2006-06-22		Shah et al.				
	10	20060149919		2006-07-06		Arizpe et al.				
If you wis	h to a	dd additional U.S. Publi						butto		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*			Kind Code4	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Line where Relevant Passages or Relevar Figures Appear			
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								-		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10816435
Filing Date		2004-03-31
First Named Inventor	G.Y.	TSAO et al.
Art Unit		2111
Examiner Name	Gopa	C. Ray
Attorney Docket Number		P19002

1	BUONADONNA, P., and D. CULLER, "Queue Pair IP. A Hybrid Architecture for System Area Networks", Proceedings of the 29th Annual International Symposium on Computer Architecture, 2002, pp. 247-255.	
2	DEYRING, K. (Ed.), "Serial ATA: High Speed Senalized AT Attachment", Rev. 1.0, August 29, 2001, 36 pp.	
3	INFINIBAND, "InfiniBand Architecture Specification Volume 1", Release 1.0, October 24, 2000, Ch. 1-8, pp. 1-195.	
4	INFINIBAND, "InfiniBand Architecture Specification Volume 1", Release 1.0, October 24, 2000, Ch. 9-10, pp. 198-445.	
5	INFINIBAND, "InfiniBand Architecture Specification Volume 1", Release 1.0, October 24, 2000, Ch. 11-14, pp. 446-669.	
6	INFINIBAND, "InfiniBand Architecture Specification Volume 1", Release 1.0, October 24, 2000, Ch. 15-20, pp. 670-880.	
7	INFINIBAND, "InfinBand Architecture Specification Volume 2", Release 1.0, October 24, 2000, Ch. 1-11, pp. 1-318.	
8	INFINIBAND, "InfiniBand Architecture Specification Volume 2", Rolease 1.0, October 24, 2000, Ch. 12-Appendix D, pp. 320-623.	
9	EP Office Action, February 9, 2006, for International Application No. 03 812 441.8-22111.	
10	PCT International Search Report, August 9, 2004, for International Application No. PCT/US03/37254.	
11	PENOKIE, G.O. (Ed.), "Information Technology-SCSI Controller Commands-2 (SCC-2)", T10Project 12250, Revision 4, September 12, 1997, 24 pp.	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

E

Application Number		10816435
Filing Date		2004-03-31
First Named Inventor	G.Y.	TSAO et al.
Art Unit		2111
Examiner Name	Gopa	C. Ray
Attorney Docket Numb	er	P19002

Date Considered

	12	RANGARJAN, M., A. BOHRA, K. BANERJEE, E.V. CARRIERA, and R. BIANCHINI, "TCP Servers Offloading TCP Processing in Informet Servers, Design, Implementation, and Performance", Technical Report, Rudgers University, 2002, pp. 1-14.						
	13	RDMA CONSORTIUM, "Architectural Specifications for RDMA over TCPIP", [online], 2005, [retrieved on December 22, 2005], retrieved from the Internet at -URL: http://www.rdmaconsortium.org/home>.						
	14	STEVENS, R.W., "UNIX Network Programming", 1990, pp. 209-210.						
	15	US Final Office Action, May 24, 2006, for US Application No. 10/615,902.						
	16	US First Office Action, December 13, 2005, for US Application No. 10/815,902.						
	17	"Virtual Interface Architecture Specification", Draft Revision 1.0, December 4, 1997, 83 pp.						
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add							
	EXAMINER SIGNATURE							

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language translation is attached.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10816435
Filing Date		2004-03-31
First Named Inventor	G.Y.	TSAO et al.
Art Unit		2111
Examiner Name	Gopa	C. Ray
Attorney Docket Numb	er	P19002

#### CERTIFICATION STATEMENT

Diagra coo	27	CED	1 07	and t	00 +	o moko	the	appropriate	coloction/c	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 197(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to fixe for information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Janaki K. Davda/	Date (YYYY-MM-DD)	2006-09-19
Name/Print	Janaki K. Davda	Registration Number	40684

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C.552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.